Revenue

The Fortune 250 retailer's 10% dividend hike reflects strong financials and a strategic navigation of a complex, evolving automotive landscape.

The utility giant is using a complex forward sale to fund massive infrastructure upgrades, balancing immediate market jitters with long-term strategic growth.

Veteran wealth architect Dr. Anna Maria Panasiuk brings her billion-dollar asset protection expertise to the prestigious Forbes Finance Council.

A new US-Taiwan partnership will equip unmanned boats with advanced AI, creating autonomous swarms to bolster the island's asymmetric defense strategy.

New Stable OS 2.0 platform uses a single wire instruction to connect digital assets with local settlement, aiming to fix cross-border payment execution.

The world's leading sports academy installs a revolutionary gel track, using 'super shoe' principles to make athletes faster, fitter, and fresher.

Disconnected tech systems create 'invisible leakage' in psychiatric practices, fueling burnout. A new approach aims to unify the operational chaos.

Despite a Q3 net loss from market volatility and one-off costs, the energy firm declared its 51st straight dividend, banking on new acquisitions for growth.

Strong Q1 results driven by Australian operations and a record gas compression backlog, offsetting a cautious North American drilling market.

The medical device maker posts its 14th straight growth quarter, with soaring profits and a strategic focus on the underserved bronchiectasis market.

Chad Eberly's recent award highlights a shift in finance, where holistic support for SMBs is proving to be the new winning formula for growth.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

The industrial giant affirms its quarterly payout, a sign of stability for investors as it navigates a costly green transition and recent regulatory hurdles.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

Andersen Group reports a 15.7% revenue jump, but IPO-related costs mask strong operational performance as the firm pursues aggressive global expansion.

As BranchOut Food preps its Q1 earnings call, investors watch to see if its patented tech and retail wins can deliver on the path to profitability.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.